Cyclic AMP-specific phosphodiesterase inhibitors

Details Cyclic AMP-specific phosphodiesterase inhibitors Cyclic AMP-specific phosphodiesterase inhibitors

2000-11-17

2002-02-19

Raymond, Richard L. (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C514S423000, C544S141000, C544S332000, C544S372000, C546S208000, C546S276400, C548S567000

Reexamination Certificate

active

06348602

ABSTRACT:

FIELD OF INVENTION
The present invention relates to a series of compounds that are potent and selective inhibitors of cyclic adenosine 3′, 5′-monophosphate specific phosphodiesterase (cAMP specific PDE). In particular, the present invention relates to a series of novel oxime and hydrazone compounds that are useful for inhabiting the function of cAMP specific PDE, in particular, PDE4, as well as methods of making the same, pharmaceutical compositions containing the same, and their use as therapeutic agents, for example, in treating inflammatory diseases and other diseases involving elevated levels of cytokines and proinflammatory mediators.
BACKGROUND OF THE INVENTION
Chronic inflammation is a multi-factorial disease complication characterized by activation of multiple types of inflammatory cells, particularly cells of lymphoid lineage (including T lymphocytes) and myeloid lineage (including granulocytes, macrophages, and monocytes). Proinflammatory mediators, including cytokinaes, such as tumor necrosis factor (TNF) and interleukin-1 (IL-1), are produced by these activated cells. Accordingly, an agent that suppresses the activation of these cells, or their production of proinflammatory cytokines, would be useful in the therapeutic treatment of inflammatory diseases and other diseases involving elevated levels of cytokines.
Cyclic adonosine monophosphate (cAMP) is a second messenger that mediates the biologic responses of cells to a wide range of extracellular stimuli. When the appropriate agonist binds to specific cell surface receptors, adenylate cyclase is activated to convert adenosine triphosphate (ATP) to cAMP. It is theorized that the agonist induced actions of cAMP within the cell are mediated pre-dominately by the action of cAMP-dependent protein kinases. The intracellular actions of cAMP are terminated by either a transport of the nucleotide to the outside of the cell, or by enzymatic cleavage by cyclic nucleotide phosphodiesterases (PDEs), which hydrolyze the 3′-phosphodiester bond to form 5′-adenosine monophosphate (5′-AMP). 5′-AMP is an inactive metabolite. The structures of cAMP and 5′-AMP are illustrated below.
Elevated levels of cAMP in human myeloid and lymphoid lineage cells are associated with the suppression of cell activation. The intracellular enzyme family of PDEs, therefore, regulates the level of cAMP in cells. PDE4 is a predominant PDE isotype in these cells, and is a major contributor to cAMP degradation. Accordingly, the inhibition of PDF Function would prevent the conversion of cAMP to the inactive metabolite 5′-AMP and, consequently, maintain higher cAMP levels, and, accordingly, suppress cell activation (see Beavo et al., “Cyclic Nucleotide Phosphodiesterases: Structure, Regulation and Drug Action,” Wiley and Sons, Chichester, pp. 3-14, (1990)); Torphy et al.,
Drug News and Perspectives,
6, pp. 203-214 (1993); Giembycz et al.,
Clin. Exp. Allergy,
22, pp. 337-344 (1992)).
In particular, PDE4 inhibitors, such as rolipram, have been shown to inhibit production of TNF&agr; and partially inhibit IL-1&bgr; release by monocytes (see Semmler et al., Int.
J. Immunopharmacol.,
15, pp. 409-413, (1993); Molnar-Kimber et al.,
Mediators of Inflammation,
1, pp. 411-417, (1992)). PDE4 inhibitors also have been shown to inhibit the production of superoxide radicals from human polymorphonuclear leukocytes (see Verghese et al.,
J. Mol. Cell. Cardiol.,
21 (Suppl. 2), S61 (1989); Nielson et al.,
J. Allergy Immunol.,
86, pp. 801-808, (1990)); to inhibit the release of vasoactive amines and prostanoids from human basophils (see Peachell et al.,
J. Immunol.,
148, pp. 2503-2510, (1992)); to inhibit respiratory bursts in eosinophils (see Dent et al.,
J. Pharmacol.,
103, pp. 1339-1346, (1991)); and to inhibit the activation of human T-lymphocytes (see Robicsek et al.,
Biochem. Pharmacol.,
42, pp. 869-877, (1991)).
Inflammatory cell activation and excessive or unregulated cytokine (e.g., TNF&agr; and IL-1&bgr;) production are implicated in allergic, autoimmune, and inflammatory diseases and disorders, such as rheumatoid artiritis;, osteoarthritis, gouty arthritis, spondylitis, thyroid associated ophthalmopathy, Behcet's disease, sepsis, septic shock, endotoxin shock, gram negative sepsis, gram positive sepsis, toxic shock syndrome, asthma, chronic bronchitis, adult respiratory distress syndrome, chronic pulmonary inflammatory disease, such as chronic obstructive pulmonary disease, silicosis, pulmonary sarcoidosis, reperfusion injury of the myocardium, brain, and extremities, fibrosis, cystic fibrosis, keloid formation, scar formation, atherosclerosis, transplant rejection disorders, such as graft vs. host reaction and allograft rejection, chronic glomerulonephritis, lupus, inflammatory bowel disease, such as Crohn's disease and ulcerative colitis, proliferative lymphocyte diseases, such as leukemia, and inflammatory dermatoses, such as atopic dermatitis, psoriasis, and urticaria.
Other conditions characterized by elevated cytokine levels include brain injury due to moderate trauma (see Dhillon et al.,
J. Neurotrauma,
12, pp. 1035-1043 (1995); Suttorp et al.,
J. Clin. Invest.,
91, pp. 1421-1428 (1993)), cardiomyopathies, such as congestive heart failure (see Bristow et al.,
Circulation,
97, pp. 1340-1341 (1998)), cachexia, cachexia secondary to infection or malignancy, cachexia secondary to acquired immune deficiency syndrome (AIDS), ARC (AIDS related complex), fever myalgias due to infection, cerebral malaria, osteoporosis and bone resorption diseases, keloid formation, scar tissue formation, and pyrexia.
In particular, TNF&agr; has been identified as having a role with respect to human acquired immune deficiency syndrome (AIDS). AIDS results from the infection of T-lymphocytes with Human Immunodeficiency Virus (HIV). Although HIV also infects and is maintained in myeloid lineage cells, TNF has been shown to upregulate HIV infection in T-lymphocytic and monocytic cells (see Poli et al.,
Proc. Natl. Acad. Sci. USA,
87, pp. 782-785, (1990)).
Several properties of TNF&agr;, such as stimulation of collaqenases, stimulation of angiogenesis in vivo, stimulation of bone resorption, and an ability to increase the adherence of tumor cells to endothelium, are consistent with a role for TNF in the development and metastatic spread of cancer in the host. TNF&agr; recently has been directly implicated in the promotion of growth and metastasis of tumor cells (see Orosz et al.,
J. Exp. Med.,
177, pp. 1391-1398, (1993)).
PDE4 has a wide tissue distribution. There are at least four genes for PDE4 of which multiple transcripts from any given gene can yield several different proteins that share identical catalytic sites. The amino acid identity between the four possible catalytic sites is greater than 85%. Their shared sensitivity to inhibitors and their kinetic similarity reflect the functional aspect of this level of amino acid identity. It is theorized that the role of these alternatively expressed PDE4 proteins allows a mechanism by which a cell can differentially localize these enzymes intracellularly and/or regulate the catalytic efficiency via post translational modification. Any given cell type that expresses the PDE4 enzyme typically expresses more than one of the four possible genes encoding these proteins.
Investigators have shown considerable interest in the use of PDE4 inhibitors as antiinflammatory agents. Early evidence indicates that PDE4 inhibition has beneficial effects on a variety of inflammatory cells such as monocytes, macrophages, T-cells of the Th-1 lineage, and granulocytes. The synthesis and/or release of many pro-inflammatory mediators, such as cytokines, lipid mediators, superoxide, and biogenic amines, such as histamine, have been attenuated in these cells by the action of PDE4 inhibitors. The PDE4 inhibitors also affect other cellular functions including T-cell proliferation, granulocyte transmigration in response to chemotoxic substances, and integrity of endothelial cell junc

Affiliated with

Also associated with

Rating

Cyclic AMP-specific phosphodiesterase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Cyclic AMP-specific phosphodiesterase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cyclic AMP-specific phosphodiesterase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2983035